Zanosar: Uses, Dosage & Side Effects
A cytotoxic alkylating agent with selective pancreatic beta-cell toxicity, used to treat neuroendocrine tumors of the pancreas (islet cell carcinomas)
Zanosar (streptozocin) is a cytotoxic chemotherapy drug belonging to the nitrosourea class of alkylating agents. It is used primarily in adults for the treatment of pancreatic neuroendocrine tumors (pNETs), also known as islet cell carcinomas. Streptozocin has a unique chemical structure that includes a glucose moiety, giving it a natural affinity for pancreatic beta cells through the GLUT2 glucose transporter. This selectivity makes it one of the cornerstone drugs in the treatment of functional and non-functional pancreatic neuroendocrine tumors. Zanosar is administered exclusively by intravenous infusion in a hospital setting and may be combined with 5-fluorouracil (5-FU) for enhanced efficacy. Kidney function must be carefully monitored throughout treatment, as nephrotoxicity is the most significant dose-limiting side effect.
Quick Facts: Zanosar
Key Takeaways
- Zanosar (streptozocin) is a cytotoxic alkylating agent specifically used to treat pancreatic neuroendocrine tumors (islet cell carcinomas) in adults, either alone or in combination with 5-fluorouracil (5-FU).
- Nephrotoxicity (kidney damage) is the most significant and dose-limiting side effect; kidney function must be monitored with blood and urine tests before, during, and after every treatment cycle.
- Severe nausea and vomiting are very common and may require anti-emetic pre-medication; dose adjustments or treatment interruption may be needed for serious adverse reactions.
- Zanosar must not be combined with live or attenuated vaccines or with other nephrotoxic drugs unless clinically essential; inform your doctor of all medications you are taking.
- Both men and women of reproductive potential must use effective contraception during treatment and for a period afterward (90 days for men, 30 days for women); breastfeeding must be discontinued.
What Is Zanosar and What Is It Used For?
Zanosar contains the active substance streptozocin, a naturally occurring chemical originally isolated from the bacterium Streptomyces achromogenes. It belongs to the nitrosourea class of alkylating agents, a group of chemotherapy drugs that work by adding alkyl groups to DNA, causing cross-links and strand breaks that prevent cancer cells from replicating. What makes streptozocin unique among alkylating agents is its glucose moiety – a sugar molecule attached to its chemical structure – which facilitates selective uptake by pancreatic beta cells through the GLUT2 (glucose transporter type 2) receptor.
This selective affinity for pancreatic tissue is what makes streptozocin particularly valuable in the treatment of pancreatic neuroendocrine tumors (pNETs). These rare tumors arise from the hormone-producing (endocrine) cells of the pancreas, known as islet cells or islets of Langerhans. Neuroendocrine tumors of the pancreas can be either functional (producing excess hormones such as insulin, glucagon, gastrin, or vasoactive intestinal peptide) or non-functional (not producing clinically significant hormone levels). Regardless of their functional status, pNETs often respond to streptozocin-based chemotherapy regimens.
Streptozocin exerts its cytotoxic effects primarily through DNA alkylation. Once inside the cell, the drug undergoes spontaneous decomposition to generate reactive alkylating species that bind to DNA bases, particularly the O-6 position of guanine. This leads to inter-strand and intra-strand DNA cross-links, single-strand breaks, and interference with DNA replication and transcription. The resulting DNA damage triggers cell cycle arrest and ultimately apoptosis (programmed cell death). Additionally, streptozocin inhibits several key enzymes involved in DNA synthesis and repair, contributing to its overall cytotoxic effect.
In clinical practice, Zanosar is used exclusively in adults and is typically administered in one of two regimen types. It may be given as monotherapy or, more commonly, in combination with 5-fluorouracil (5-FU), a pyrimidine antimetabolite that provides complementary anticancer activity. The combination of streptozocin and 5-FU has been a cornerstone of treatment for advanced or metastatic pancreatic neuroendocrine tumors for several decades, supported by clinical trial data demonstrating improved response rates and survival outcomes compared with either agent alone.
The European Neuroendocrine Tumor Society (ENETS) and the European Society for Medical Oncology (ESMO) both recommend streptozocin-based chemotherapy as a first-line systemic treatment option for patients with advanced, well-differentiated (grade 1-2) pancreatic neuroendocrine tumors, particularly those with a high tumor burden or rapidly progressive disease. Similarly, the National Comprehensive Cancer Network (NCCN) guidelines include streptozocin-based regimens among the recommended systemic therapy options for unresectable or metastatic pNETs.
Unlike most chemotherapy drugs, streptozocin has a natural affinity for pancreatic cells. Its glucose-like molecular structure allows it to enter cells via the GLUT2 transporter, which is highly expressed on pancreatic beta cells and many pancreatic neuroendocrine tumor cells. This selective uptake concentrates the drug at the tumor site, potentially improving efficacy while reducing some systemic side effects. However, this same mechanism also explains why streptozocin can cause damage to normal pancreatic beta cells, occasionally leading to glucose intolerance or diabetes-like symptoms.
What Should You Know Before Receiving Zanosar?
Contraindications
There are specific situations in which Zanosar must not be used. Your healthcare team will carefully assess these factors before initiating treatment to ensure your safety.
- Hypersensitivity: Do not receive Zanosar if you are allergic to streptozocin or any of the other ingredients (anhydrous citric acid and sodium hydroxide for pH adjustment).
- Severe renal impairment: Zanosar is contraindicated in patients with severe kidney failure, as the drug is nephrotoxic and could worsen kidney function to a dangerous degree.
- Live vaccines: Zanosar must not be used in combination with live or live-attenuated vaccines, as the immunosuppressive effects of chemotherapy may lead to serious or fatal vaccine-derived infections.
- Breastfeeding: It has not been established whether streptozocin passes into breast milk. As a precaution, breastfeeding must be discontinued during treatment with Zanosar.
Warnings and Precautions
Kidney damage is the most significant and potentially severe side effect of Zanosar. Your doctor will monitor your kidney function with regular blood and urine tests before, during, and after treatment. If you notice any changes in urination patterns, swelling, or unusual fatigue, report these to your healthcare team immediately. Dose adjustments or treatment discontinuation may be necessary if kidney function deteriorates.
Before and during treatment with Zanosar, your doctor needs to be aware of the following important considerations:
- Kidney function: Because streptozocin is directly toxic to the kidneys, your renal function must be carefully assessed and monitored throughout treatment. Blood tests (serum creatinine, blood urea nitrogen) and urine tests (proteinuria, glucose) will be performed regularly. Any pre-existing kidney problems should be discussed with your doctor before starting treatment.
- Liver function: Streptozocin can have harmful effects on the liver. Liver function tests should be performed regularly during treatment to detect any liver damage early. Signs of liver toxicity include elevated liver enzymes, abnormally low blood albumin levels (hypoalbuminemia), and jaundice.
- Blood counts: Zanosar can cause hematological toxicity, including decreases in red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). Regular complete blood counts are essential during treatment. Low blood counts can increase your susceptibility to infections and bleeding.
- Blood sugar: Due to its effects on pancreatic beta cells, streptozocin may cause glucose intolerance (changes in blood sugar levels). These effects are usually mild to moderate and typically reversible, but blood glucose should be monitored during treatment.
- Nausea and vomiting: Severe nausea and vomiting are very common with streptozocin and may sometimes require treatment interruption. Your doctor will typically prescribe anti-emetic medications (drugs to prevent nausea) before and during treatment.
- Extravasation risk: Zanosar is a vesicant, meaning it can cause tissue damage if it leaks outside the vein during infusion. If you experience burning, pain, or tenderness at the injection site during your infusion, tell your nurse or doctor immediately. Tissue necrosis (death) can occur at the injection site if extravasation happens.
Your treatment will be given under the supervision of a physician experienced in the use of cytotoxic chemotherapy drugs. They will determine how to monitor your tolerance of the treatment through regular clinical examinations and laboratory tests.
Children and Adolescents
The safety and efficacy of Zanosar have not been established in children and adolescents under 18 years of age. Zanosar is currently approved only for use in adult patients. If a pediatric patient presents with a pancreatic neuroendocrine tumor, treatment decisions should be made on a case-by-case basis by a multidisciplinary team with experience in both pediatric oncology and neuroendocrine tumors.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before receiving this medication. Streptozocin, like most cytotoxic chemotherapy drugs, has the potential to cause harm to the developing fetus and affect fertility.
- Contraception: Both men and women of reproductive potential must use effective contraception during treatment with Zanosar. After treatment ends, contraception should continue for at least 90 days for men and 30 days for women.
- Pregnancy: You should not receive Zanosar if you are pregnant, planning to become pregnant, or not using contraception. Streptozocin has the potential to cause birth defects and other harm to the unborn child. If you become pregnant during treatment, inform your doctor immediately.
- Breastfeeding: It has not been established whether streptozocin passes into breast milk. As a precaution, you must stop breastfeeding during treatment with Zanosar to protect your infant from potential exposure to the drug.
- Male fertility: If you are a man being treated with Zanosar, you should avoid fathering a child during treatment and for at least 90 days after the last dose. You should seek advice about sperm cryopreservation (sperm banking) before starting treatment, as streptozocin may permanently affect male fertility.
Driving and Using Machines
Zanosar may cause confusion, fatigue, or depression. If you experience any of these effects, you should not drive or operate machinery. You are responsible for assessing whether you are fit to drive or perform tasks requiring alertness. The side effects described elsewhere in this article should be considered when making this assessment. Discuss any concerns with your doctor or pharmacist.
Each vial of Zanosar contains 30.1 mg of sodium (the main component of table salt), which corresponds to approximately 1.5% of the maximum recommended daily sodium intake for an adult. This should be taken into account for patients on a controlled sodium diet.
How Does Zanosar Interact with Other Drugs?
Drug interactions can significantly affect the safety and efficacy of Zanosar. Your healthcare team will carefully review all your current medications before starting treatment. Some combinations are absolutely prohibited, while others require careful monitoring and possible dose adjustments.
Prohibited Combinations
The following drug combinations must be avoided when receiving Zanosar:
- Nephrotoxic drugs: Zanosar must not be given together with or immediately after other medications that are toxic to the kidneys, unless your doctor determines the benefit outweighs the risk. Examples include aminoglycoside antibiotics (gentamicin, tobramycin), amphotericin B, cisplatin, and non-steroidal anti-inflammatory drugs (NSAIDs) at high doses. The combination significantly increases the risk of severe and potentially irreversible kidney damage.
- Live or live-attenuated vaccines: Immunosuppression caused by Zanosar may lead to a risk of serious, potentially fatal generalized disease from live vaccines. Examples include measles-mumps-rubella (MMR), varicella (chickenpox), BCG, yellow fever, and oral polio vaccines.
Combinations Requiring Caution
The following medications may interact with Zanosar and require careful monitoring:
| Interacting Drug | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| 5-Fluorouracil (5-FU) | Synergistic anticancer effect | Intentional combination; enhanced efficacy against pNETs | Used together per protocol; monitor for additive toxicity |
| Immunosuppressants | Additive immunosuppression | Increased risk of infections and lymphoproliferative disorders | Monitor closely; watch for signs of infection |
| Oral anticoagulants (vitamin K antagonists) | Altered anticoagulant effect | Increased risk of bleeding or thrombosis | Monitor INR frequently; adjust anticoagulant dose |
| Nephrotoxic agents | Additive kidney damage | Significantly increased risk of severe nephrotoxicity | Avoid unless essential; intensive renal monitoring |
| Live vaccines | Risk of generalized vaccine disease | Potentially fatal infection from vaccine strain | Contraindicated; use inactivated vaccines only |
Always inform your doctor, pharmacist, or nurse about all medications you are currently taking, have recently taken, or might take in the future. This includes prescription drugs, over-the-counter medications, herbal remedies, vitamins, and dietary supplements. Some interactions may not be immediately apparent, and your healthcare team needs a complete picture of your medication regimen to ensure safe treatment.
What Is the Correct Dosage of Zanosar?
Zanosar may only be prepared and administered by qualified healthcare professionals in a hospital or clinical setting. Your doctor will determine the appropriate dose based on your body surface area (BSA, measured in square meters) and your overall health status. Treatment requires strict medical supervision, including regular clinical examinations and laboratory tests.
Adults
Two primary dosing schedules are used for Zanosar in the treatment of pancreatic neuroendocrine tumors:
Schedule 1: Every 6 Weeks
Dose: 500 mg/m²/day intravenously for 5 consecutive days, repeated every 6 weeks.
This schedule continues until maximum therapeutic benefit is achieved or treatment-limiting toxicity is observed. It provides higher dose intensity over the 5-day treatment period, followed by a longer recovery interval.
Schedule 2: Every 3 Weeks
Cycle 1: 500 mg/m²/day intravenously for 5 consecutive days.
Subsequent cycles: 1000 mg/m² as a single infusion every 3 weeks.
This schedule allows more frequent dosing with a single-day infusion after the initial loading cycle, which may be more convenient for some patients.
Other dosing regimens with similar dose intensity have been used in clinical studies with comparable efficacy and safety results. The optimal duration of maintenance therapy with Zanosar has not been definitively established. For patients with functional tumors, serial monitoring of biological markers (such as chromogranin A, insulin, or gastrin levels) allows determination of biochemical response. For all patients, response can be assessed through measurable reductions in tumor size on imaging studies (CT, MRI, or PET scans).
| Schedule | Dose | Frequency | Infusion Duration |
|---|---|---|---|
| 6-Week Cycle | 500 mg/m²/day × 5 days | Every 6 weeks | 30 min – 4 hours |
| 3-Week Cycle (Initial) | 500 mg/m²/day × 5 days | Cycle 1 only | 30 min – 4 hours |
| 3-Week Cycle (Maintenance) | 1000 mg/m² single dose | Every 3 weeks | 30 min – 4 hours |
Children
Zanosar has not been studied in children or adolescents under 18 years of age. There are no established pediatric dosing recommendations. Use in this population is not currently approved.
Elderly Patients
No specific dose adjustments are recommended for elderly patients based on age alone. However, elderly patients may have reduced kidney and liver function, which may require more careful dose selection and monitoring. Kidney function should be assessed before each treatment cycle, and dose adjustments should be made based on renal parameters rather than age.
Dose Adjustments
Dose adjustments or treatment interruptions may be necessary if you experience serious adverse effects, particularly nephrotoxicity, hematological toxicity, or severe gastrointestinal effects. Your doctor will determine whether to reduce the dose, delay treatment, or discontinue therapy based on the type and severity of the side effects observed. Anti-emetic pre-medication is recommended routinely to help manage nausea and vomiting.
Overdose
There is no specific antidote for Zanosar overdose. If an overdose occurs, treatment consists of supportive care measures. Overdose should be prevented through careful calculation of the dose to be administered, which is always performed by your healthcare team based on your body surface area. If you suspect you have received more Zanosar than intended, contact your doctor or emergency services immediately.
Administration of Zanosar requires hyperhydration (increased fluid intake) to help protect the kidneys. Your healthcare team will ensure you receive adequate intravenous fluids before, during, and after each infusion to minimize the risk of nephrotoxicity. This is a critical component of the administration protocol.
What Are the Side Effects of Zanosar?
Like all chemotherapy drugs, Zanosar can cause side effects, although not everyone will experience them. Some side effects can be serious and require immediate medical attention, while others are manageable with supportive care. Your healthcare team will monitor you closely throughout treatment to detect and address side effects promptly.
Very Common
May affect more than 1 in 10 patients
- Severe nausea and vomiting (sometimes requiring treatment interruption)
- Diarrhea
Common
May affect up to 1 in 10 patients
- Nephrotoxicity (kidney damage), which can be severe – monitored through blood and urine tests
Not Known
Frequency cannot be estimated from available data
- Blood disorders: Decreased hematocrit (proportion of red blood cells), decreased white blood cells, decreased platelets; increased susceptibility to infections
- Metabolic effects: Glucose intolerance (changes in blood sugar levels), usually mild to moderate and typically reversible
- Neurological effects: Confusion, fatigue, depression
- Kidney effects: Nephrogenic diabetes insipidus (inability of kidneys to concentrate urine)
- Liver effects: Hepatotoxicity with elevated liver enzymes, abnormally low albumin levels (hypoalbuminemia)
- Injection site reactions: Tissue necrosis (tissue death) if the drug leaks outside the vein; burning sensation extending from the injection site up the arm
- General: Fever
Nephrotoxicity – The Most Important Side Effect
Nephrotoxicity (kidney damage) deserves special attention as it is the most clinically significant and dose-limiting side effect of streptozocin. The mechanism involves direct toxic damage to the renal tubules, leading to proteinuria (protein in the urine), glycosuria (glucose in the urine), increased serum creatinine, and potentially renal tubular acidosis. In severe cases, kidney failure can occur. The risk of nephrotoxicity increases with cumulative dose and is heightened by concurrent use of other nephrotoxic agents or pre-existing kidney disease.
To minimize the risk of kidney damage, your doctor will perform renal function tests before every treatment cycle. These include measurements of serum creatinine, blood urea nitrogen (BUN), creatinine clearance, and urinalysis for proteinuria and glucose. Adequate hydration (hyperhydration) during and after each infusion is essential to help protect the kidneys. If signs of kidney impairment are detected, your doctor may reduce the dose, delay treatment, or discontinue therapy entirely.
Hematological Effects
While hematological toxicity (effects on blood cells) is listed as frequency “not known,” it is a recognized side effect of streptozocin therapy. Decreases in white blood cells (leukopenia), red blood cells (anemia), and platelets (thrombocytopenia) can occur. Low white blood cell counts increase your risk of infections, while low platelet counts increase the risk of bleeding. Complete blood counts should be performed regularly during treatment. Your doctor may prescribe growth factors or adjust your treatment schedule if significant blood count decreases are observed.
Gastrointestinal Effects
Nausea and vomiting are the most frequently reported side effects of Zanosar, occurring in a large majority of patients. These symptoms can be severe enough to require treatment interruption in some cases. Modern antiemetic protocols, including 5-HT3 receptor antagonists (such as ondansetron), dexamethasone, and NK1 receptor antagonists (such as aprepitant), can significantly reduce the severity of chemotherapy-induced nausea and vomiting. Your doctor will typically prescribe antiemetic pre-medication before each Zanosar infusion.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorized is important, as it allows continuous monitoring of the benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store Zanosar?
Proper storage of Zanosar is essential to maintain its efficacy and safety. In a hospital setting, storage and handling are managed by your pharmacist and nursing team, but understanding the storage requirements can help you appreciate the care taken in preparing your treatment.
- Before opening: Store in a refrigerator at 2–8°C. Keep the vial in the outer carton to protect it from light. The powder is light-sensitive and must not be exposed to direct light.
- After reconstitution: The reconstituted solution should be diluted immediately. Once diluted, the solution has been shown to be chemically and physically stable for up to 24 hours at 25°C (room temperature).
- No preservatives: Zanosar contains no preservatives and is intended for single use only. From a microbiological perspective, unless the method of reconstitution and dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, storage conditions are the responsibility of the user.
- Expiry date: Do not use Zanosar after the expiry date shown on the vial (EXP). The expiry date refers to the last day of the indicated month.
- Disposal: Do not dispose of medications via wastewater or household waste. Ask your pharmacist about proper disposal procedures for unused chemotherapy drugs. These measures help protect the environment.
Keep all medications out of the sight and reach of children. Zanosar is a potent cytotoxic drug and must be handled only by trained healthcare professionals using appropriate protective equipment.
What Does Zanosar Contain?
Active Ingredient
The active substance is streptozocin. Each vial contains 1 g of streptozocin. Streptozocin (also known as streptozotocin) is a glucosamine-nitrosourea compound with the molecular formula C8H15N3O7 and a molecular weight of approximately 265.22 g/mol. It was originally isolated from the soil bacterium Streptomyces achromogenes and was first identified for its antibiotic properties before its selective pancreatic beta-cell toxicity and antitumor activity were discovered.
Excipients
- Anhydrous citric acid: Used as a buffer to maintain the pH of the solution
- Sodium hydroxide: Used for pH adjustment
Appearance and Packaging
Zanosar is supplied as a sterile white to pale yellow powder for infusion preparation in a glass vial. Each carton contains 1 vial. Before administration, the powder must be reconstituted with 9.5 mL of sodium chloride 9 mg/mL (0.9%) solution, producing a light golden-colored solution with a pH of approximately 4. After reconstitution, each mL contains 100 mg of streptozocin. The reconstituted solution must then be further diluted in 500 mL of sodium chloride 0.9% before infusion. When co-administered with 5-fluorouracil, a Y-set infusion system is recommended.
Zanosar is a cytotoxic drug that requires careful handling. Preparation must be performed by trained personnel in designated areas using appropriate protective equipment including long-sleeved gowns, safety masks, protective caps, goggles, and sterile disposable gloves. If the powder or solution comes into contact with skin or mucous membranes, wash the affected area immediately with soap and water. Pregnant women should be warned to avoid handling cytotoxic agents. Waste disposal must follow institutional protocols for hazardous chemotherapy waste, including incineration in appropriately labeled rigid containers.
Frequently Asked Questions About Zanosar
Zanosar (streptozocin) is used to treat pancreatic neuroendocrine tumors (pNETs), which are also known as islet cell carcinomas. These are rare tumors that develop from the hormone-producing cells of the pancreas. They can be either functional (producing excess hormones like insulin or glucagon) or non-functional. Streptozocin is often considered a first-line chemotherapy option for advanced, well-differentiated pNETs, either as a single agent or in combination with 5-fluorouracil (5-FU). International guidelines from ENETS, ESMO, and NCCN all include streptozocin-based regimens among recommended treatments.
Zanosar is given following one of two standard schedules. In the 6-week cycle, it is administered at 500 mg/m² per day for 5 consecutive days, repeated every 6 weeks. In the 3-week cycle, the initial cycle consists of 500 mg/m² per day for 5 consecutive days, followed by a single infusion of 1000 mg/m² every 3 weeks for subsequent cycles. Each infusion lasts between 30 minutes and 4 hours. The choice of schedule depends on your doctor’s clinical judgment and your individual response to treatment.
Kidney monitoring is critical because nephrotoxicity (kidney damage) is the most significant and dose-limiting side effect of streptozocin. The drug can cause direct damage to the renal tubules, leading to proteinuria, glycosuria, elevated creatinine, and potentially kidney failure. The risk increases with cumulative dose exposure. Your doctor will check your kidney function with blood tests (serum creatinine, BUN) and urine tests (protein, glucose) before each treatment cycle. If signs of kidney impairment are detected, the dose may be reduced or treatment suspended to prevent permanent damage. Adequate hydration during infusions also helps protect the kidneys.
Yes, Zanosar is frequently used in combination with 5-fluorouracil (5-FU) for the treatment of pancreatic neuroendocrine tumors. This combination has been shown to improve response rates compared with either drug alone. When used together, Zanosar and 5-FU are administered using a Y-set infusion system. However, Zanosar should not be combined with other drugs that are toxic to the kidneys (nephrotoxic agents) unless absolutely necessary, as this significantly increases the risk of serious kidney damage. Your doctor will carefully assess the risks and benefits of any combination therapy.
Severe nausea and vomiting are very common with Zanosar. Your doctor should prescribe anti-emetic (anti-nausea) medications before each treatment session. Modern antiemetic protocols typically include drugs like ondansetron, dexamethasone, and sometimes aprepitant. If your nausea is not adequately controlled, tell your healthcare team immediately – they can adjust your anti-emetic regimen or modify the treatment schedule. Staying well hydrated, eating small frequent meals, and avoiding strong odors may also help manage symptoms. In some cases, severe nausea may require treatment interruption until symptoms improve.
Zanosar is the most widely recognized brand name for streptozocin. It is approved across the European Economic Area and in many other countries. In some markets, particularly in Belgium and Italy, it may be marketed under the name “Streptozocine Keocyt” or “Streptozocina Keocyt.” Regardless of the brand name, the active substance is the same: 1 g of streptozocin per vial, supplied as a powder for reconstitution. The marketing authorization holder is Esteve Pharmaceuticals S.A.S., with manufacturing by Valdepharm in France.
References
- European Medicines Agency (EMA). Zanosar – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed February 2026.
- U.S. Food and Drug Administration (FDA). Streptozocin – Prescribing Information. Available at: www.accessdata.fda.gov. Accessed February 2026.
- Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(7):844–860.
- Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153–171.
- Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine. 1992;326(8):519–523.
- Dilz LM, Denecke T, Grozinsky-Glasberg S, et al. Streptozocin/5-Fluorouracil Chemotherapy Is Associated with Durable Response in Patients with Advanced Pancreatic Neuroendocrine Tumours. European Journal of Cancer. 2015;51(10):1253–1262.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2025.
- British National Formulary (BNF). Streptozocin Monograph. Available at: bnf.nice.org.uk. Accessed February 2026.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Oncology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of medical experts
Evidence Standards
GRADE framework – Level 1A evidence from systematic reviews and RCTs
Guidelines
WHO, EMA, FDA, ENETS, ESMO, NCCN
All content is independently reviewed by specialist physicians. iMedic has no commercial funding or pharmaceutical company sponsorship. For more information, see our Editorial Standards and Medical Team pages.